Initial intuition
Perez Taboada et al. (Nature Microbiology 2026) have just characterized a family of bacterial Schlafen proteins acting as anti-phage ribonucleases: they cleave host tRNAs to block the translation of newly synthesized viral proteins. The human SLFN11 protein has exactly the same mechanism—it restricts viral replication by targeting eukaryotic tRNAs—and it is known to potentiate DNA-damaging chemotherapies (Murai 2018).
Bacterial Schlafen are smaller and structurally more accessible than SLFN11 (~500 vs ~900 aa, single AAA+ domain architecture vs multi-domain). They open a rare window in medicinal chemistry: using the prokaryotic system as a first-pass structural template to design probes against the corresponding human target.
Hypothesis
The structural alignment of bacterial Schlafen with human SLFN11 should reveal conserved pockets at the active site (RNase) and at the tRNA recognition site common enough so that a hit identified against the bacterium is reasonably transferable to the human enzyme.
The goal is not antibacterial activity, but the design of activating allosteric modulators of SLFN11—which could:
- Potentiate the innate antiviral response in patients with partial immunodeficiency (HIV, transplant recipients, immunosuppression).
- Sensitize chemoresistant tumors (SLFN11 is a major predictive biomarker of response to PARP/Top1 inhibitors).
In silico plan
-
Structural alignment: retrieve AlphaFold structures of the V1 identified bacterial Schlafen (
A0A4U8YPX3,A0A975BF37,A0A975BI32,A0A975BUB4) and human SLFN11 (Q7Z7L1). Align via Mol* + DALI to identify conserved residues. -
RNase active site: characterize the target pocket—metal coordination (Zn²⁺ or Mg²⁺), catalytic residues (likely Glu/Asp/His). Compare with other known ribonucleases (RNase A, angiogenin, RNase T2) for a transferability bonus.
-
Virtual screening: ZINC20 lead-like library (~5M compounds) docking on the identified pockets of bacterial Schlafen. Top-1% filtering by Vina scoring + redocking on human SLFN11.
-
Selectivity: exclude hits that strongly match RNase A or other essential human RNases (ribonucleopathies).
Limitations and risks
- The crystallographic structure of SLFN11 in complex with a tRNA is not public in 2026. Substrate binding mode inference must rely on homologous models or long MD.
- Ribonuclease activity against tRNAs is intrinsically dangerous: a global activator of SLFN11 in uninfected tissues would cause generalized tRNA depletion and severe toxicity. The realistic strategy is likely a conditional activator (allosteric, triggered by viral or oncological stress), not a direct activator.
- The therapeutic window for RNase modulators is notoriously narrow (cf. the setbacks of ribavirin-like derivatives).
Links to the Bactaegion scope
V1 Family Bacterial Schlafen (added by Gemini iter 2 audit), host-directed modality. Seminal paper Perez Taboada 2026 (Nature Microbiology, DOI 10.1038/s41564-026-02277-8). This hypothesis is arguably the closest to the “ideal host-directed target” identified in the family sheet.